1 This paper describes the pharmacology of the novel a2-adrenoceptor antagonist fluparoxan (GR 50360) which is currently being studied clinically as a potential anti-depressant. Idazoxan and yohimbine were included in many studies for comparison. 2 In the rat isolated, field-stimulated vas deferens and the guinea-pig isolated, field-stimulated ileum preparations, fluparoxan was a reversible competitive antagonist of the inhibitory responses to the a2-adrenoceptor agonist UK-14304 with pKB values of 7.87 and 7.89 respectively. In the rat isolated anococcygeus muscle, fluparoxan was a much weaker competitive antagonist of the contractile response to the a1-adrenoceptor agonist phenylephrine with a pKB of 4.45 giving an a2: a1-adrenoceptor selectivity ratio of greater than 2500. 3 In the conscious mouse, fluparoxan (0.2-3.0mgkg-1) was effective by the oral route and of similar potency to idazoxan in preventing clonidine-induced hypothermia and antinociception. In the rat, UK-14304-induced hypothermia (ED50 = 1.4mgkg-1, p.o. or 0.5mgkg-', i.v.) and rotarod impairment (ED50 = 1.1 mgkg-' p.o. or 1.3 mgkg-1, i.v.) were antagonized by fluparoxan. Fluparoxan, 0.67-6 mg kg-1, p.o., also prevented UK-14304-induced sedation and bradycardia in the dog. 4 In specificity studies fluparoxan had low or no affinity for a wide range of neurotransmitter receptor sites at concentrations up to at least 1 x 10-s M. It displayed weak affinity for 5-HTlA (pIC50 = 5.9) and 5-HT15 (pKj = 5.5) binding sites in rat brain.
Introduction Methods
The classification of x-adrenoceptors into xl and a2 subtypes is well recognised (see McGrath et al., 1989) . Both agonists and antagonists for these subtypes are known and have proved to be useful therapeutically. However, highly selective antagonists at a2-adrenoceptors are relatively novel, e.g.
Merck 912 (Pettibone et al., 1987) , CH38083 (Vizi et al., 1988) and RS-15385-197 (Clark et al., 1989) , and await therapeutic evaluation. The autoreceptor on noradrenergic neurones mediating the feedback inhibitory effects of noradrenaline is widely recognised as belonging to the a2-subtype (Langer, 1980) . Antagonists at this receptor facilitate noradrenergic neurotransmission as evidenced by a rapid increase in noradrenaline turnover (Anden et al., 1982; Walter et al., 1984 ). An C2-adrenoceptor antagonist could therefore be beneficial in conditions such as depression which have been associated with a deficiency of noradrenaline in the CNS (Schildkraut, 1965) . Several novel a2-adrenoceptor antagonists with varying degrees of a2-to oe1-adrenoceptor selectivity have been described since the appearance of imiloxan in 1981 (Michel & Whiting, 1981) and idazoxan in 1983 (Doxey et al., 1983) . We describe here the in vitro and in vivo pharmacology of the novel benzodioxinopyrrole, fluparoxan (formerly known as GR50360), (Figure 1) , a potent and selective a2-adrenoceptor antagonist that is currently undergoing clinical evaluation. Preliminary accounts of some of the data reported here were presented to the British Pharmacological Society (Halliday et al., 1988a,b) .
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Rat vas deferens
The prostatic halves of vasa deferentia were carefully removed from adult Sprague-Dawley rats (300400g; Charles River) killed by stunning and cervical dislocation.
The tissues were mounted under 0.5 g tension at 31°C in oxygenated Krebs-Henseleit solution. Electrical stimulation was provided through two stainless steel ring electrodes, 20 mm apart, placed around the tissue and consisted of supramaximal rectangular monophasic pulses of 2ms duration and approximately 20V amplitude delivered every lOs. Twitch responses were recorded isometrically by use of Ormed Dynamometer UFI strain-gauge transducers. UK-14304 or clonidine was added to the bath in incremental doses to produce cumulative inhibitory concentration curves. For antagonist studies the antagonist drugs were added 25-30min before addition of the agonist.
Guinea-pig ileum
Guinea-pig terminal ileum (3cm lengths) was obtained from male Dunkin Hartley guinea-pigs (450-550g; Porcellus) killed by cervical dislocation. The tissues were set up under 0.5 g C Macmillan Press Ltd, 1991 tension in 12.5 ml jacketed organ baths in oxygenated Krebs-Henseleit solution at 360C and subjected to electrical field stimulation as described by Drew (1978) . Twitch responses were recorded isometrically as for rat vas deferens. After equilibration, the tissues were exposed to either fresh Krebs-Henseleit solution or Krebs-Henseleit solution containing antagonist for 15-30min. Successive doses of UK-14304 were then added to the bath to produce a cumulative inhibition of the twitch response, each dose being added when the previous dose had produced its maximal inhibitory effect.
Rat anococcygeus muscle
Anococcygeus muscles were dissected from male Sprague-Dawley rats (300-400g; Charles River) killed by stunning and cervical dislocation. Tissues were soaked overnight for 17h at 40C in Krebs-Henseleit solution containing 6hydroxydopamine, 1 x 10-3 M, to destroy presynaptic sites of uptake and noradrenaline release as described by Doggrell (1980) . The anococcygeus muscles were then mounted under 1 g tension in 12.5 ml organ baths and washed repeatedly with oxygenated Krebs-Henseleit solution at 360C for 1 h. Thereafter the tissues were attached to isometric strain gauge transducers and the tension reduced to 0.5 g. The tissues were primed with high doses of phenylephrine (final bath concentration of 6 x 10-6M) and a 30s contact time until reproducible contractions were obtained. The maximum contractile response of each tissue to either phenylephrine or methoxamine was measured and tissues were then washed with fresh Krebs-Henseleit solution and incubated with either this solution or Krebs-Henseleit solution containing antagonist for a period of 15-30 min. Concentration-response curves were obtained by cumulative addition of either phenylephrine or methoxamine, each dose being added after the previous dose had produced its maximum effect.
Rabbit aorta
Lengths of aorta (8 cm approx.) were removed from adult rabbits (Froxfield NZW) killed by cervical dislocation. Excess fatty tissue was removed from the aorta which was then threaded on to a 20mm diameter glass rod and cut helically into strips approximately 4 mm wide and 4 cm long. The strips were mounted under 0.5 g tension in oxygenated Krebs-Henseleit solution at 370C in 15 ml organ baths. Agonistinduced contractures were recorded isometrically. Four cumulative dose-response curves to phenylephrine were obtained for each tissue strip. The antagonist was introduced at least 15 min before the fourth curve. The shift in the agonist potency between the third and fourth curves was then calculated after correcting for any sensitivity change calculated from tissues not exposed to antagonist. The largest sensitivity change was usually between the first and second curves, hence the design employed here.
Estimation ofpotency in vitro
Lateral displacements of agonist concentration-response curves were measured at the control half-maximal response level. The negative logarithm of the dissociation constant of each antagonist (pKB) was calculated using the Schild/ Gaddum equation (Gaddum, 1957) from the relationship: pKB = log (dose-ratio -1) -log [antagonist] where doseratio (DR) is the ratio of the agonist concentration producing half maximal responses (IC50) in the presence and absence of the antagonist at the molar concentration [antagonist] . Individual pKB determinations were made using 3 or 4 concentrations for each antagonist such that a mean (+s.e.) pKB value could be calculated. The results were also plotted according to the method of Arunlakshana & Schild (1959) to yield Schild plot gradients. The effect of each concentration of antagonist was measured on 1-6 preparations of a given tissue, each from a separate animal.
Antagonism of clonidine-induced hypothermia in the mouse
Male mice (Glaxo CRH 20-26 g), housed in groups of 5 at room temperature (22°C), were given gum acacia 5% w/v (vehicle), fluparoxan or idazoxan orally in a dose volume of 10mlkg-'. After 60min the oesophageal temperature of each mouse was recorded with an electronic thermistor probe (Comark) and clonidine, 0.15mgkg-1, was given intraperitoneally. Temperatures were remeasured 30min later and the changes in temperature were calculated.
Antagonism of clonidine-induced antinociception in the mouse
Male mice (Glaxo CRH 20-26g) were given vehicle (5% w/v gum acacia 10mlkg-1), fluparoxan, idazoxan or yohimbine; 60 min later either saline or clonidine, 0.05 mg kg-1, was given subcutaneously. After another 30 min each mouse received an intraperitoneal injection of 0.25 ml phenylbenzoquinone, 0.02% w/v, and was observed for 10min for the appearance of abdominal constriction accompanied by stretching.
Antagonism of UK-14304-induced hypothermia and rotarod impairment in the rat Male hooded rats (70-120g; Glaxo) were given vehicle (5% w/v gum acacia-oral route; 0.9% w/v sodium chloride solution-intravenous route), fluparoxan or idazoxan by either the oral or intravenous (tail vein) routes (10 ml kg-1 and 5mlkg-' dose volume respectively). After 30min the oesophageal temperature of each rat was recorded with an electronic thermistor probe (Comark) and either 0.9% w/v sodium chloride solution or UK-14304 (2 mg kg-') was given subcutaneously (5mlkg-1 dose volume). Oesophageal temperature was recorded again after an additional 30min; 10min later each rat was placed on an accelerating rotarod (Jones & Roberts, 1968) and the time it remained on the revolving drum was measured.
Antagonism of UK-14304-induced sedation and bradycardia in the dog Studies were performed in beagles (6 males, 6 females; Glaxo; 6.8-10kg weight range). Fluparoxan was given orally (0.22-6mgkg-' in gelatin capsules) 30min before a subcutaneous injection of UK-14304 (0.05mg kg-'). Sedation and heart rate were measured before giving fluparoxan and at various times after injection of UK-14304. For sedation, both spontaneous activity and reactivity to an audible stimulus (hand clap) were assessed on pairs of dogs housed in their home kennel and again when placed alone in an unfamiliar environment. Behaviour each time was scored from 0 (inactive) to 6 (maximal activity) such that by combination of the 4 behavioural scores a maximum activity score of 24 was possible. Heart rate was measured by counting the number of pulses in the femoral artery in 30 s.
Estimation ofpotency in vivo
The potencies of test compounds in antagonizing M2-adrenoceptor agonist-induced behavioural effects were calculated in the form of ED50 values. For antagonism of antinociceptive effects the data were quantal and ED50 values were used to represent the dose of antagonist reducing the incidence of the response to half that of the control animals.
This was obtained from the best line fit to a log dose-logit plot of the quantal data. Confidence limits (95%) were obtained by use of Fieller's theorem. For antagonism of the hypothermia and sedation, the ED50 value represents the dose of antagonist reducing the magnitude of the response to 50% of that in animals given agonist alone. Half maximal response values and standard errors were obtained by fitting dose-response curves to the data by the computer programme ALLFIT (De Lean et al., 1978) .
Evaluation of activity or affinity at non a-adrenoceptor sites fi-Adrenoceptors Affinity for fJl-adrenoceptors was assessed in the rat (male 200 g; Glaxo AHA strain) isolated, electrically stimulated left atrium by a method based on that of Blinks (1965) . The isolated atrium was impaled on a two pin electrode and placed in a 2 ml organ bath in oxygenated Krebs-Henseleit solution and stimulated at 1 Hz and 2 ms using just suprathreshold voltage.
Activity at f2-adrenoceptors was measured in guinea-pig (Dunkin Hartley male 300-400g; Porcellus) isolated trachea as described by Coleman & Nials (1989) .
Dopamine receptors The effect of fluparoxan at functional peripheral dopamine receptors was assessed by use of dopamine-induced increases in mesenteric blood flow in the anaesthetized dog for D1-receptor-mediated effects as described by Hilditch & Drew (1984) and dopamine-induced inhibition of electrically stimulated increases in heart rate of the anaesthetized cat for D2-receptor-mediated effects (Dallas et al., 1986) .
Radioligand binding assays for the D2 site were performed on rat striatal membranes. Corpora striata were obtained from male hooded rats (200-250 g; Glaxo) killed by stunning and decapitation. The tissues were homogenized in 30 volumes of 50mM Tris-HCl buffer at 40C and pH 7.4 in an Ultra-Turrax homogeniser (lowest setting for two periods of 10 s with 30s on ice in between). The homogenate was centrifuged (40000 g for 20 min at 4°C) and the resulting pellet Responses were recorded isometrically (Ormed Dynamometer UF1 transducer) from 2 cm lengths of tissue under 0.5 g tension in oxygenated Krebs-Henseleit solution in 10 ml organ baths at 37°C. Fluparoxan was tested at concentrations up to 1 x 10-5 M against the contractile response to muscarine with a 5 min dosing cycle.
For radioligand binding assays rat heart and cerebral cortex membranes were prepared in a HEPES buffer (20 mm HEPES + 100 mm sodium chloride + 0.5 mm EDTA at pH 7.4; buffer for heart membranes also contained 3 mm magnesium chloride). Radioligands were [3H]-N-methylscopolamine (72 Ci mmol-1, Amersham International, 0.2 nM) for the heart assays and [3H]-pirenzepine (87 Ci mmol-1, Dupont NEN, 0.8 nM) for cortex. Atropine (1 pM) was used to define specific binding and assays were terminated after 90 min at 22°C by centrifugation (Lazareno & Roberts, 1989) .
Histamine receptors Lengths of terminal ileum obtained from male Dunkin Hartley guinea-pigs (450-500g; Porcellus) were set up as described above. The effect of fluparoxan on histamine Hl -receptors was assessed from concentrationresponse curves obtained to histamine in tissues preincubated for 30 min in fresh Krebs-Henseleit solution or Krebs-Henseleit solution containing fluparoxan. Assays for hista-mine H2-receptor activity were performed on histamine-induced tachycardia in guinea-pig atrium as described by Humphray et al. (1982) . 5-Hydroxytryptamine (5-HT)-receptors Possible activity of fluparoxan at functional 5-HT1-like receptors in dog saphenous vein and 5-HT2 receptors in rabbit isolated aorta was assessed as described by Feniuk et al. (1985) . Afflinity for 5-HT1A and 5-HTIB binding sites was measured with rat (male hooded; Glaxo; 150-200g) hippocampal and striatal membranes respectively. Hippocampi from 8 rats were pooled and homogenized in an Ultra-Turrax at its lowest setting for 10s at 5YC in 10 vol of 50mM Tris-HCl buffer, pH 7.4. The membrane preparation was centrifuged at 40000 g for 15 min and the pellet was resuspended in 10 volumes of Tris-HCl buffer. A further centrifugation and re-suspension of the membranes was followed by a 10 min incubation at 370C to remove endogenous 5-HT. Following the final centrifugation, the resulting pellet was resuspended in 10 vol of 50mM Tris-HCI buffer, pH 7.4 at 37°C. Binding assays were performed using 100pl aliquots (equivalent to 0.16-0.2mg protein). The membranes were incubated for 15min at 37°C with [3H]-8hydroxy-2-(di-n-propylamino) tetralin (85Cimmol-1, Amersham International 0.5-1.0mM) and the test compound in a final volume of 250p14. 5-HT, 1 x 10-5M, was used to define specific binding. Assays were terminated by filtration through Whatman GF/B filters using a Brandel Cell Harvester. Affinity for 5-HT1B binding sites in rat striatum was determined with [1251]-cyanopindolol (2088 Ci mmol-1, Amersham International) according to Hoyer et al. (1985) .
Noradrenaline uptake
Male Hooded rats (250-300g; Glaxo) were killed by stunning and decapitation. Brains were quickly removed and the occipital cortex dissected out. Occipital cortices from three rats were placed in 5.1 ml of ice-cold 0.32 M sucrose solution in a 10ml Potter-Elvehjem glass mortar fitted with a Teflon pestle having a clearance of 0.25 mm. The tissue was homogenized twice at 840r.p.m. each time using six complete up and down strokes of the pestle over a 30s period with a 60s pause with the mortar on ice in between. The homogenate was then centrifuged at 1000g and 4°C for 10min. The supernatant (crude synaptosomal preparation) was used immediately for uptake studies. Assays were performed in triplicate using 0.1 ml of the synaptosomal preparation added to 1.8 ml of an oxygenated Krebs-Henseleit buffer at 37°C. The buffer had the following composition (mM): NaCI 118, KCl 4.7, MgSO4 1.1, KH2PO4 1.2, NaHCO3 25, CaCI2 1.3, D-glucose 10, ascorbic acid 0.5 and pargyline HCl 0.1; pH 7.5 and contained either no drug, fluparoxan or desmethylimipramine with or without ouabain (final concentration 10mM). After 10min, 0.1ml of [3H]-noradrenaline (41Cimmol-1, Dupont NEN) in Krebs-Henseleit buffer was added (final concentration 10 nM) and the tubes incubated in a shaking water-bath for 7min. The samples were then filtered through Whatman GF/B filters using a Brandel Cell Harvester. The filters were washed with cold (4°C) buffer (2 x 5ml) and the amount of radioactivity retained measured by liquid scintillation spectroscopy.
Specific and energy-dependent noradrenaline uptake was defined as the difference between that in the presence and absence of ouabain. The concentration of fluparoxan and desmethylimipramine inhibiting by 50% the specific noradrenaline uptake was determined from concentration inhibition-dose-response curves analysed using the logistic curve-fitting programme ALLFIT (De Lean et al., 1978) .
Effect on [3H]-dihydroalprenolol binding sites
Male Sprague-Dawley rats (300 g; Charles River) were given water (5 ml kg-1), fluparoxan (6 or 12mg kg-1), amitriptyline (30mg kg-') or fluparoxan (6mg kg-1) + amitriptyline (30mgkg-1) by the oral route twice daily (at 08 h 00min and 17 h 00 min) for 6 days. Fifteen hours after the final dose the rats were killed by stunning and decapitation, their brains rapidly removed and the cerebral cortices obtained and cleared of adhering white matter. Each cerebral cortex (350-450mg wet wt.) was rapidly frozen in liquid nitrogen and stored at -70°C for up to three weeks. Membranes for radioligand binding assays were prepared from the thawed cerebral cortices as described by Wise & Halliday (1985) . The binding assays were performed on 0.2 ml aliquots of cerebral membranes incubated initially in triplicate in 50 mM Tris-HCl buffer (final volume of 1 ml, pH 7.8) at 25°C for 10min. Thereafter, 0.1 ml [3H]-dihydroalprenolol (1-[propyl-3H(N)]dihydroalprenolol HCl, 40 Ci mmol -1, Dupont NEN) was added and the mixture incubated at 25°C for 25 min followed by filtration through Whatman GF/B filters in a Brandel Cell Harvester. The filters were washed (3 x 5 ml Tris-HCl buffer at 25°C) and the retained tritium measured by addition of the filters to 1Oml Pico-Fluor 30 scintillation fluid (United Technologies Packard) for approximately 15 h followed by conventional liquid scintillation spectrometry. (-)-Isoprenaline (200pM) was included in some tubes and specific binding was calculated as the difference between binding in its absence and presence.
The density of binding sites (Bmax) and their affinity (KD) were determined by Scatchard analysis (Scatchard, 1949) of the binding of six concentrations (0.1-2.0 nM) of [3H]-dihydroalprenolol.
In some studies fluparoxan, amitriptyline and (-)-isoprenaline were tested over a range of concentrations for their ability to displace specific binding of [3H]-dihydroalprenolol (0.3 nM) from cerebrocortical membranes from untreated rats. The respective concentrations producing 50% displacement of specific binding (IC50) and hence K; values and Hill slopes were determined by log probit analysis.
Drugs and solutions
Tissues were bathed in a modified Krebs-Henseleit solution (Apperley et al., 1976) unless otherwise stated. The solution was gassed with 95% 02 and 5% CO2. For rat vas deferens and ileum preparations the buffer solution contained 2.5mM
CaCl2 and for guinea-pig ileum experiments 2yM (+ )-propranolol was included. Reagents used were A.R. grade and purchased from commercial sources. The following drugs were used: fluparoxan (GR50360, trans-( ± )-5-fluoro-2,3,3a,9atetrahydro -lH[1,4] -benzodioxino -[2,3 -c]pyrrole hydrochloride, Glaxo Group Research Ltd); amitriptyline hydrochloride (Sigma); atropine sulphate (Sigma); (+)-butaclamol hydrochloride (Research Biochemicals Inc.-RBI); clonidine hydrochloride (Sigma); desmethylimipramine hydrochloride (Ciba-Geigy); dopamine hydrochloride (Sigma); histamine hydrochloride (Sigma); 6-hydroxydopamine hydrochloride (Sigma); 5-hydroxytryptamine creatinine sulphate (Sigma); idazoxan hydrochloride (Glaxo Group Research Ltd); (-)isoprenaline sulphate (Sigma); ketanserin (RBI); methoxamine hydrochloride (Burroughs Wellcome); muscarine chloride (Sigma); ouabain octahydrate (Sigma); pargyline hydrochloride (Sigma); phenylbenzoquinone (Kodak); a-phenylephrine hydrochloride (Koch Light); (+)-propranolol hydrochloride (ICI); spiperone hydrochloride (RBI); UK-14304 (5-bromo-6-[2-imidazolin-2-ylamino]-quinoxaline, Pfizer); yohimbine hydrochloride (Sigma).
Drug solutions were prepared immediately before use and for in vivo experiments the doses refer to the free base.
Results
Antagonism of c2-adrenoceptor selective agonists on the rat vas deferens and guinea-pig ileum UK-14304 and clonidine produced a concentration-dependent inhibition of the twitch response of the rat isolated field-stimulated vas deferens. Inhibition in excess of 90% was produced by UK-14304, 2 x 10-8M, and clonidine, 1 x 10-7M, respectively. Fluparoxan (0.25-50 x 10-7M), idazoxan (0.25-10 x 10-7M) and yohimbine (1-100 x 10-7M) produced concentration-dependent, parallel rightward displacements of agonist concentration-inhibitory response curves with no suppression of the maximum attainable inhibitions. The results for fluparoxan are shown in Figure 2 . The Schild plots (Arunlakshana & Schild, 1959) yielded straight lines with gradients not significantly different from unity except for the antagonism of clonidine by fluparoxan where the gradient was 1.29. The pKB values and Schild plot gradients are shown in Table 1 .
Fluparoxan (0.1-10 x 10-6M), idazoxan (0.25-10 x 10-7M) and yohimbine (0.1-10 x 10-6M) were also potent and competitive antagonists of the inhibitory action of UK-14304 on the guinea-pig isolated and field-stimulated ileum. (1.10) 6.25 + 0.08 (0.91) NT * Slope significantly different from unity (linear regression analysis). pKB = (dose-ratio -1) -log [antagonist] where dose-ratio is the ratio of the agonist concentration producing half maximal responses in the presence and absence of the antagonists at the molar concentration [antagonist] .
The effect of increasing concentrations of fluparoxan on the inhibitory potency of UK-14304 and the resulting Schild plots are shown in Figure 3 . For fluparoxan, idazoxan and yohimbine the mean pKB values + standard errors obtained were 7.89 + 0.07 (Schild slope 1.04), 8.13 + 0.04 (Schild slope 0.92) and 7.64 + 0.06 (Schild slope 0.98) respectively. In a separate study of the antagonism of UK-14304 in the rat vas deferens, fluparoxan was compared with its two enantiomers. There were no differences in potencies. Thus for the racemate (+)fluparoxan and (-)-fluparoxan the respective mean pKB values (± standard errors and Schild plot gradients) were 7.86 + 0.07 (slope = 1.09), 7.88 + 0.08 (slope = 0.99) and 7.68 + 0.06 (slope = 1.04).
Antagonism of contractions produced by ax-adrenoceptor selective agonists on the rat anococcygeus muscle Fluparoxan (0.1-10 x 10-M), idazoxan (0.01-10 x 10-5M) and yohimbine (0.1-10 x 10-5M) were also competitive antagonists of phenylephrine-induced contractions of the rat isolated anococcygeus muscle. The effects of increasing concentrations of fluparoxan are shown in Figure 2 . All three compounds were weaker antagonists of a1-adrenoceptors than of a2-adrenoceptors. Fluparoxan had at least 50 times lower affinity than that of the other two antagonists. The affinity constants and Schild slopes obtained are shown in Table 1 C.) 
Antagonism ofphenylephrine-induced contraction of the rabbit aortic strip
Fluparoxan behaved as a competitive antagonist of phenylephrine-induced contractions of the aortic strip producing a mean (± s.e.) pKB value of 4.32 + 0.06 (slope = 1.01). In separate studies with idazoxan, concentrations in excess of 1 x 10-5M occasionally produced a weak contraction of the tissue (up to 10% of the phenylephrine maximum). Idazoxan also behaved as a competitive antagonist of phenylephrine in this tissue (mean pK, = 5.79 + 0.08; slope = 0.83).
Antagonism of clonidine-induced hypothermia and antinociception in the mouse
In the conscious mouse, fluparoxan and idazoxan were of similar potency in preventing the hypothermia produced by clonidine 0.15mgkg-1 i.p. Clonidine caused a fall in oesophageal temperature of 1.77 + 0.33°C (mean + s.e.; n = 10).
This was prevented dose-dependently by oral fluparoxan, 0.2-3.0mgkg-(15%-93%). In a second study, clonidine-induced hypothermia was 2.5 + 0.2°C (mean + s.e.; n = 16) which was prevented dosedependently by oral idazoxan 0.13-3.0mgkg-' (16%-76%).
The oral doses of fluparoxan and idazoxan required to reduce by half the clonidine induced hypothermia were 0.68 + 0.10 and 0.84 + 0.09 mg kg-1 respectively.
In another study, fluparoxan and its two enantiomers were of similar potency in producing dose-related inhibitions of the hypothermia caused by clonidine. The oral ED50 values for the racemate, (+)-fluparoxan and (-)-fluparoxan for inhibition of hypothermia were 0.66 + 0.10, 0.73 + 0.13 and 0.46 + 0.06 mg kg-1 respectively.
In the antinociception study, an intraperitoneal injection of phenylbenzoquinone caused a characteristic abdominal constriction response that was abolished by pretreatment with clonidine 0.05mgkg-' s.c. Oral doses of fluparoxan, 0.38-3mgkg-1, idazoxan, 0.25-2.0mgkg-' and yohimbine, 0.63-5mgkg-', prevented this antinociceptive action of clonidine dose-dependently and with similar potencies (Figure 4) . The ED50 values were 0.75 (0.54-1.07), 0.65 (0.4-1.03) and 1.10 (0.28-1.94) mg kgorally respectively.
Antagonism of UK-14304 induced hypothermia and impaired rotarod performance in the rat
In the rat UK-14304, 2 mg kg's.c., produced hypothermia of 4-50C and a marked impairment of rotarod performance. All animals, except the saline controls, received clonidine, 0.05mgkg-1 s.c., and either vehicle, fluparoxan, idazoxan or yohimbine orally at one of the stated doses. The proportion of animals exhibiting at least one abdominal constriction response over the following 10min is indicated by the shaded histograms.
Both effects of the a2-adrenoceptor agonist were prevented dose-dependently by fluparoxan and idazoxan ( Figure 5 ). Fluparoxan was of similar potency by either route of administration unlike idazoxan which, although similar in potency to fluparoxan following intravenous dosing, was much weaker when given orally.
Antagonism of UK-14304-induced sedation and bradycardia in the dog UK-14304 (0.05mgkg-' s.c.) caused marked sedation and bradycardia in beagles that was apparent after 30 min, peaked at 2-3 h and persisted for more than 5 h. Fluparoxan, 0.22-6mgkg-1 orally, prevented both effects of UK-14304 in a dose-related fashion and the antagonism Behaviour was scored subjectively, a reduced score representing sedation. Heart rate was obtained by palpating the femoral artery. Predose values were obtained before giving either treatment. active at most non-a-adrenoceptor sites investigated (Table 2) . 0-.At functional muscarinic sites in rat ileum there was no activ-0.1 1.0 100 ity at 1 x 10-5M and only weak affinity for muscarinic M1 binding sites in rat cerebral cortex and M2 sites in rat heart. In functional models fluparoxan was tested for both agonist and antagonist activity. In binding assays pIC50 represents the negative logarithm of the molar concentration of fluparoxan preventing by 50% the specific binding of the competing drug. In some studies a pK value was obtained by the method of Cheng & Prusoff (1973) . pKB is as defined in Table 1. giving IC50 values of 8.8 x 10-5M and 5 x 10-9M respectively.
Effects of rat cerebrocortical [3H]-dihydroalprenolol binding sites
Both fluparoxan and amitriptyline were very weak displacers of [3H]-dihydroalprenolol binding to cerebrocortical membranes from untreated rats with pKi values (Hill slopes) of 4.05 (0.71) and 3.64 (1.05) respectively. For isoprenaline, the pKi was 6.38 and the Hill slope was 0.69. The effect of twice daily, oral dosing with fluparoxan 6 and 12mgkg-1, amitriptyline 30mgkg-' or a combination of both drugs for 6 days on the density of binding sites is shown in Table 3 . The number of binding sites (B,,) was reduced by fluparoxan (9% and 21%) and amitriptyline (31%) without affecting their affinity (KD) for the radioligand. The greatest reduction (40%) was produced in rats treated with the combination of fluparoxan, 6 mg kg-, and amitriptyline 30 mg kg 1.
Discussion
Fluparoxan behaves as a novel, competitive antagonist having very high selectivity for a2-adrenoceptors. The pKB values against the X2-adrenoceptor responses induced by the selective agonists UK-14304 and clonidine in rat vas deferens and guinea-pig ileum (Brown et al., 1979; Drew, 1978 ) ranged from 7.86-7.91. Agonist concentration-response curves were displaced in a parallel fashion and the data gave straight line Schild plots which, with one exception, had slopes which were not significantly different from unity indicating competitive antagonism. The Schild-plot slope for the antagonism of clonidine by fluparoxan in the rat vas deferens was 1.23. The reason for the high value is not clear and requires further investigation. However, the pKB values obtained for idazoxan and yohimbine were in agreement with generally quoted liter-ature values. Fluparoxan was a much weaker competitive antagonist of the a1-adrenoceptor selective agonists phenylephrine and methoxamine in rat anococcygeus muscle and rabbit aorta preparations. The pKB values obtained in rat vas deferens and anococcygeus muscle showed fluparoxan to have at least 1000 fold L%2-: ax-adrenoceptor selectivity making it one of the most selective a2-adrenoceptor antagonists so far described. Many x-adrenoceptor antagonists with an imidazoline moiety display partial agonist activity (Ruffolo, 1983) . For example, idazoxan displays partial a1-adrenoceptor agonism in some tissues including rabbit isolated aorta (Dalrymple et al., 1983 ). In the present study, idazoxan, at high concentrations, sometimes caused a weak contraction of the rabbit aorta preparation. In contrast, fluparoxan, which does not have an imidazoline group, did not show any a-adrenoceptor agonist activity in this or any other preparation examined.
In studies to measure the a2-adrenoceptor antagonism produced in vivo, fluparoxan was effective by the oral route and of similar potency to idazoxan in preventing clonidine-induced hypothermia and antinociception in the mouse. Similarly, in the rat, fluparoxan prevented the hypothermia and impaired rotarod performance caused by UK-14304. Fluparoxan showed similar potency by both the oral and intravenous routes of administration indicating good oral bioavailability.
To interpret these antagonist effects it is important to consider the nature of the agonist-induced response. The hypothermia produced by clonidine, although in part a consequence of stimulation of x2-adrenoceptors in the brain, could have a histamine H2-receptor mediated component (Bugajski et al., 1980) . While amphetamine-like drugs and aladrenoceptor agonists also prevent clonidine-induced hypothermia (unpublished data) fluparoxan does not have histamine H2-receptor antagonist, fi-adrenoceptor agonist or amphetamine-like activity.
The prevention of clonidine-and UK-14304-induced hypothermia is therefore most probably attributable to blockade of central a2-adrenoceptors. The antinociceptive activity of clonidine also appears to be a2-adrenoceptor-mediated (Paalzow & Paalzow, 1976; Skingle et al., 1982) , but could have been produced both at peripheral and at central sites (Bentley et al., 1977; Spaulding et al., 1979; Reddy et al., 1980) . Impairment of rotarod performance appears to reflect the sedative effects of CX2-adrenoceptor agonists and is believed to be a centrallymediated action (Drew et al., 1979) . In the dog, fluparoxan prevented both the sedative and cardiovascular responses to UK14304 with a sustained duration of action. The in vivo findings with fluparoxan are therefore indicative of potent and effective antagonism of a2-adrenoceptors at sites in the CNS. Further studies would be needed to show whether the compound displays differential activity at pre-and postsynaptic a2-adrenoceptors in the CNS, as could be shown by comparing potencies against clonidine induced mydriasis and hypoactivity (Heal et al., 1989) , or for a2A and a2B subtype binding sites (Bylund, 1988) . Fluparoxan is a racemate. Dabire et al. (1983) reported significant differences in the selectivity and potency of the enantiomers of idazoxan. In contrast, there were no significant differences between the enantiomers of fluparoxan in terms of a2and ocl-adrenoceptor antagonism in rat tissues in vitro and for their oral potency in preventing clonidine-induced hypothermia in the mouse. This was the anticipated result because fluparoxan is essentially a planar molecule and the two enantiomers are virtually superimposable. This contrasts with the enantiomers of idazoxan where the imidazoline side chain lies outside of the plane of the benzodioxan moiety.
In specificity studies, fluparoxan showed no appreciable affinity or activity at histamine Hor H2-receptors, muscarinic acetylcholine receptors, #2-adrenoceptors, dopamine D1 or D2 receptors or functional 5-HT1-like receptors in the dog saphenous vein. The antagonist action of fluparoxan at fil-adrenoceptors was about 1000 times less than that at CX2-adrenoceptors. Fluparoxan displaced [3H]-8-OH-DPAT and [3H]-cyanopindolol binding to 5-HTlA and 5-HTIB sites respectively, but only at concentrations between 100 and 1000 times its affinity for a2-adrenoceptors.
Twice daily administration of fluparoxan to rats for six days resulted in a significant reduction in the number of cerebro-cortical [3H]-dihydroalprenolol binding sites with no reduction in affinity. Other x2-adrenoceptor antagonists have been shown to produce this change (Swann et al., 1981; Brown et al., 1990) which could reflect an adaptation to a chronically increased synaptic concentration of noradrenaline since a2-adrenoceptor antagonists are known to increase noradrenaline turnover (Anden et al., 1982; Walter et al., 1984; Scheinin & Virtanen, 1986) . Uptake inhibitors and monoamine oxidase inhibitors also bring about this adaptive change (Sellinger-Barnette et al., 1980) . Inhibition of uptake is unlikely to explain why fluparoxan decreases [3H]-dihydroalprenolol binding site density because it has only very weak affinity for the uptake site. Furthermore, in separate unreported studies we have found that, unlike known monoamine oxidase inhibitors, fluparoxan does not prevent the depressant effects of tetrabenazine or the pressor and mydriatic effects of orally administered tyramine in rodents. The greatest reduction in the density of [3H]-dihydroalprenolol binding sites occurred in rats given both fluparoxan and amitriptyline. This has been found with other OC2-adrenoceptor antagonists when coadministered with uptake inhibitors (Johnson et al., 1980) and is consistent with a synergistic effect on noradrenaline turnover (Halliday & Ford, 1983) .
In conclusion, fluparoxan is a novel, competitive a2-adrenoceptor antagonist in isolated tissues with a very high a2to al-adrenoceptor selectivity ratio. The results of in vivo studies indicate good bioavailability and a potent action mediated at x2-adrenoceptors in the CNS. The most likely therapeutic use for fluparoxan is in the treatment of depression, and in common with known antidepressant drugs fluparoxan reduces the density of rat cerebrocortical [3H]dihydroalprenolol binding sites (Baneree et al., 1977) .
